Vincera Pharma, Inc. (VINC)
| Market Cap | 282.48M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 8.20M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $20.37 |
| Previous Close | $20.93 |
| Change ($) | -0.56 |
| Change (%) | -2.68% |
| Day's Open | 20.92 |
| Day's Range | 19.83 - 21.17 |
| Day's Volume | 35,100 |
| 52-Week Range | 9.35 - 21.67 |
News
PALO ALTO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer throug...
Business combination transaction with LifeSci Acquisition Corp. was completed on December 23, 2020
About VINC
Vincera Pharma, a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The company's product pipeline includes VIP152 that is in Phase 1 clinical trials for the treatment of solid tumors/nonHodgkin lymphoma and acute myeloid leukemia; VIP236, a small molecule drug conjugate for solid tumors; VIP943 for the treatment of leukemias and myelodysplastic syndromes; and VIP924 for B-cell malignancies. It also develops VIP217, an oral PTEFb/CDK9 inhibitor. The compan... [Read more...]
| Industry Biotechnology | Founded 2019 |
| CEO Dr. Ahmed M. Hamdy | Employees 2 |
| Stock Exchange NASDAQ | Ticker Symbol VINC |
Analyst Forecasts
According to one analyst, the rating for Vincera Pharma stock is "Strong Buy" and the 12-month stock price forecast is 33.00.